Loading
Combination Therapy / Antibody-drug Conjugates / Neoplasms · Journal article
Drug Delivery · August 5, 2026
Reinforces what was already believed, rather than introducing something new.
This retrospective pharmacovigilance analysis of 19,697 FDA FAERS adverse event reports identifies ADC-specific toxicity profiles driven by molecular structure (target, payload, linker) and combination context. The findings confirm that NECTIN-4 ADCs cause skin reactions, TROP2 causes gastrointestinal toxicity, FRα and TF cause ocular disorders, and topoisomerase I inhibitors increase respiratory toxicity and mortality, with non-cleavable linkers amplifying hepatobiliary risk. These structure-toxicity correlations are clinically relevant for risk stratification but derive from observational data without prospective control groups or efficacy comparisons.
Retrospective pharmacovigilance study with disproportionality analysis and multivariable logistic regression. Patients with solid tumors receiving approved ADCs (monotherapy or combinations); represented through FDA FAERS adverse event reports.. Intervention: Seven approved antibody-drug conjugates in monotherapy or combination regimens. n = 19,697.
19,697 adverse event reports analyzed for seven approved ADCs from FDA FAERS (Q1 2004 to Q1 2025) NECTIN-4 targeting linked to skin reactions; TROP2 to gastrointestinal toxicities; FRα and TF to ocular disorders Topoisomerase I inhibitor payloads associated with increased respiratory toxicity and mortality
Pharmacovigilance data subject to underreporting bias and confounding by indication; no prospective control group No efficacy or comparative effectiveness data reported; analysis focuses solely on safety signals
Clinicians should use these structure-toxicity correlations to anticipate and monitor ADC-specific safety risks: expect dermatologic surveillance for NECTIN-4 agents, GI monitoring for TROP2, ophthalmologic assessment for FRα/TF agents, and heightened respiratory monitoring for topoisomerase I inhibitor ADCs. Combination regimens require additional vigilance for accelerated toxicity onset with ICIs and delayed onset with other partners.
Large real-world pharmacovigilance study of 19,697 adverse event reports confirms known structure-toxicity relationships for ADCs, but lacks comparative efficacy data and uses observational methods without prospective controls.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should use these structure-toxicity correlations to anticipate and monitor ADC-specific safety risks: expect dermatologic surveillance for NECTIN-4 agents, GI monitoring for TROP2, ophthalmologic assessment for FRα/TF agents, and heightened respiratory monitoring for topoisomerase I inhibitor ADCs. Combination regimens require additional vigilance for accelerated toxicity onset with ICIs and delayed onset with other partners.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The expanding clinical use of Antibody-Drug Conjugates (ADCs) necessitates a clearer understanding of their real-world toxicity profiles across diverse clinical settings. This retrospective pharmacovigilance study analyzed 19,697 adverse event (AE) reports for seven approved ADCs from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q1 2025). Using disproportionality analysis validated by multivariable logistic regression, we identified safety signals for both monotherapy and combination regimens. The analysis revealed that toxicity profiles are strongly driven by an ADC's molecular structure and treatment setting. Target-specific 'on-target, off-tumor' effects were prominent, linking Nectin cell adhesion molecule 4 (NECTIN-4) targeting to skin reactions, Trophoblast cell-surface antigen 2 (TROP2) to gastrointestinal toxicities, and both folate receptor α (FRα) and tissue factor (TF) to ocular disorders. Furthermore, payload and linker types drove distinct toxicities; topoisomerase I inhibitors were associated with increased respiratory toxicity and mortality, while non-cleavable linkers conferred a significantly stronger risk of hepatobiliary toxicity. Combination regimens not only amplified specific risks, such as endocrine disorders with immune checkpoint inhibitors (ICIs), but also fundamentally reshaped toxicity kinetics, accelerating AE onset with ICIs while significantly delaying it with other combinations. This real-world analysis confirms that ADC toxicities are highly specific to their molecular design and clinical context, highlighting that understanding these complex structural and kinetic interplays is essential for optimizing safety management in clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.